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In this pilot study, we evaluated effects of intraarticular botulinum toxin type A (BoNT-A) in an equine model of acute synovitis. In humans, BoNT-A is used in the treatment of disorders of excessive muscle contraction, 1 but recently it has been recognized as a therapy for pain disorders, including chronic arthritis pain in humans. 2 The literature regarding the use of BoNT-A in pain is growing, with more than 180 reports, reviews, or original studies in humans or animals published in the peer-reviewed medical literature between 1993 and 2007. For example, in humans, BoNT-A was reported as beneficial for a wide variety of painful conditions, including dystonia, [3] [4] [5] headache, 6 -8 anal fissure, 9 piriformis syndrome, 10 chronic biliary pain, 11 painful urologic disorders, 12, 13 and temporomandibular dysfunction. 14 In animals, antinociceptive effects of BoNT-A have been characterized in rodents, [15] [16] [17] but clinical use of BoNT-A in veterinary practice for painful disorders has not been forthcoming. BoNT-A, produced by the bacterium Clostridium botulinum, binds to presynaptic nerve terminals, where it inhibits release of acetylcholine. 18 BoNT-A can reduce pain associated with cervical dystonia, 3, 19, 20 cervicogenic headaches, [21] [22] [23] [24] and migraine 25 -an effect independent of muscle contraction that is possibly caused by inhibition of neurotransmitters involved in pain transmission, including glutamate and substance P. 15 Recently, use of BoNT-A as an intra-articular treatment for refractory joint pain in humans has been reported. 2 Clinical benefit was observed, without local or systemic adverse effects. However, no hypothesis testing or randomized clinical trials have been reported in the literature to confirm or refute these initial observations. Because ethical considerations limit the extent of clinicopathologic studies of painful joints in human patients, we performed clinicopathologic studies of painful joints in horses. (Joint pain is among the most common causes of lameness in horses, 1, 26 and lameness can be objectively quantified.) Here, we tested the hypothesis that BoNT-A can attenuate lameness associated with acute synovitis in an equine model.
MATERIALS AND METHODS Animals
The institutional animal care and use committee approved all methods reported in the present investigation. This translational study was designed as a pilot to evaluate the effects of an experimental intervention in an equine model of acute synovitis. It was conducted at a university veterinary medical teaching hospital. Four horses 2-6 yrs of age, with clinically normal carpi, were studied. Horses were isolated for 2 wks, vaccinated (Eastern equine encephalomyelitis, Western equine encephalomyelitis, equine influenza, and tetanus), treated with a broad-spectrum anthelmentic to eliminate any intestinal parasites, and trained to trot on a highspeed treadmill before initiation of the study. Before the administration of test substances, a kinematic gait analysis for evaluation of lameness was conducted on each horse. 27 Horses were randomly assigned (two each) to either placebo (saline) or treatment (BoNT-A) groups.
Experimental Interventions
Either BoNT-A or saline was given into the middle carpal joints, followed 2 wks later by injection of recombinant equine interleukin-1 beta (IL-1␤) 28 to induce acute synovitis. We subsequently compared clinical and clinicopathologic changes in the injected joints between the two groups. Four horses were randomly assigned, two each, to either an experimental group or a control group. At baseline (day 0), synovial fluid was collected from the right and left middle carpal joints of all subjects, followed immediately by injection of the study drug or a placebo. The experimental group (n ϭ 2) was treated with 50 units of BoNT-A (BOTOX, Allergen, Inc., Irvine, CA), and the control group (n ϭ 2) was treated with an equivalent volume (1 ml) of 0.9% saline by intra-articular injection into both middle carpal joints. The dose (50 units of BoNT-A) was empirically chosen on the basis of the clinical experience of one of the authors (M.K.C.). Two weeks later (day 14), fluid was collected from both joints, and IL-1␤ (100 ng) was injected into one randomly selected middle carpal joint in all horses ( Table 1) . The opposite middle carpal joint in each horse was injected with an equal volume (1 ml) of 0.9% saline.
Clinical Evaluation
Horses were evaluated for objective (pulse rate, temperature, respiratory rate, capillary refill time) and subjective (appetite, defecation, mucous membrane color, attitude, hydration, borborygmi) indicators of general health, neurologic function (each horse's quality of movement, strength, and coordination, evaluated subjectively by observing the horse walking and trotting), evidence of synovitis (effusion, periarticular edema, response to flexion and deep palpation of the carpi, range of motion, joint circumference), and evaluation of lameness every 12 hrs for 2 days and 1 day, respectively, after intra-articular injections on days 0 and 14. Lameness is traditionally evaluated with the horse moving at the trot (two-beat gait) in a straight line on a hard surface. The horse is evaluated for any asymmetry of head and/or pelvic movement indicating pain in a particular limb. The horse's limbs are then stressed to evaluate or exacerbate subtle lameness in an attempt to isolate pain by holding each joint in flexion for 30 -90 secs, and then having the horse trot off. Horses were observed a minimum of once daily for evaluation of general health, signs of synovitis, and lameness on days 3-13.
Synovial Fluid Analysis
Synovial fluid (1 ml) was aspirated by arthrocentesis using a 20-gauge, 1.5-inch, hypodermic needle. Fluid was assessed for color, transparency, total nucleated cell count, specific gravity, total protein content, mucin clot analysis, and cytologic examination.
Lameness Evaluation
Computer-assisted kinematic evaluation of lameness was used to objectively measure lameness, 29 an indirect measure of joint pain in horses. 30 Briefly, this method is based on measurement of the temporal asymmetry of vertical head motion during the stride. True vertical head motion is measured without outof-plane artifact by collecting three-dimensional head displacement using several high-speed cameras surrounding the field of view. Reflective markers (2.5 cm in diameter) are attached to the subject, and their head movement is tracked over time. Asymmetry of vertical head movement, a biomechanical effect of unilateral forelimb lameness, is quantified by a moving-window, curve-fitting, error-correction algorithm that decomposes the vertical head-movement signal into regularly repeating (periodic) and random parts. Processing of the periodic part is used to quantify temporal asymmetry and lameness. Vertical movement of the right-forelimb foot is used to locate vertical head position in time during the stride. One measure of unilateral forelimb lameness is the difference in head minimum position between the soundand lame-forelimb stance phases (MINDIFF). In a horse with unilateral forelimb lameness, the head moves down to a lower position during the stance phase of the nonlame (sound) limb because the force of landing is greater and the downward inertia of the body and head is greater. To reduce the force of landing, the horse uses its neck muscles to move upward. This decreases the downward inertia of the body during the stance phase of the lame limb; thus, the minimum vertical position of the head is higher during the stance phase of the lame limb.
In this study, horses were evaluated by kinematic analysis of lameness by calculating the MINDIFF for each stride and the mean MINDIFF over all strides during a single trial while horses were trotting at a moderate speed (4 m/sec) on a treadmill. Each trial lasted 30 secs, during which data from about 40 strides were collected. Four trials of 30 secs (or about 120 strides) were collected, and the mean MINDIFF for all four trials was calculated for each treatment time. Because of the small sample size (n ϭ 4), statistical methods to test for differences between groups were not considered appropriate and were, therefore, not applied in the kinematic analysis. Traditional subjective gait analysis was conducted in parallel with kinematic gait analyses by two blinded investigators experienced in lameness evaluation. Horses were evaluated while trotting in a straight line and after 1 min of carpal flexion (bilaterally). Observations were localized to a limb, with the severity scored according to established guidelines of the American Association of Equine Practitioners. 31 Briefly, grade 0 is defined as soundness or no lameness perceptible under any circumstances (e.g., weight carrying, circling, inclines, hard surface, etc.); grade 1 as difficult to observe or not consistently apparent, regardless of circumstances; grade 2 as difficult to observe at a walk or when trotting in a straight line, but consistently apparent under certain circumstances; grade 3 as consistently observable at a trot under all circumstances; grade 4 as obvious, with marked nodding, hitching, or shortened stride; and grade 5 as lameness so severe as to cause the animal to have minimal or no weight bearing in motion and/or at rest, or an inability to move.
Postmortem
On day 15, horses were euthanatized by intravenous injection of 87 mg/kg of sodium pentobarbital. The middle carpal joints were opened and synovial fluid was collected for analysis. Gross pathologic evaluation of the middle carpal joints was conducted. Samples of synovial membrane were removed from the dorsal aspect of each joint, and full-thickness cartilage samples were harvested from the distal articular surfaces of the radiocarpal and intermediate carpal bones and the radial and intermediate facets of the third carpal bone.
Histology
Samples selected for histologic evaluation were fixed in 10% neutral buffered formalin, and 5-m sections were cut with a microtome. Synovium samples were stained with hematoxylin and eosin and evaluated and graded by a blinded evaluator for signs of cellular infiltration, synovial intimal hyperplasia, subintimal edema, subintimal fibrosis, and vascularity. 32 
RESULTS

General Effects
Physical examinations were within normal limits in all horses after the initial experimental interventions and before IL-1␤ administration on day 14. Neurologic examinations were within normal limits throughout the 15-day study. No clinically apparent adverse effects were seen after intraarticular administration of 50 units of BoNT-A.
Synovial Fluid Analysis and Histology
At baseline and before administration of IL-1␤, synovial fluid analyses were within normal limits (data not shown). However, on day 15, synovial fluid analysis was consistent with acute suppurative inflammation in all joints injected with IL-1␤: the total protein content was 8.3, 6.3, 6.8, and 6.3 g/dl, and the total nucleated cell count was 137,000, 75,800, 85.800, and 88,100/l in subjects 1, 2, 3, and 4, respectively. Fluid analyses of joints injected with either saline alone or with both saline and BoNT-A were within normal limits (not shown). On day 15 (1 day after IL-1␤ injection), histologic and cytologic evidence of acute suppurative inflammation was observed in all IL-1␤injected joints (Fig. 1A) , whereas no pathologic changes were observed in samples taken from joints injected with either saline alone or with both saline and BoNT-A (Fig. 1B) .
Lameness Assessment
Clinical evaluation (not shown) indicated that both horses in the control group (injected with saline on day 0) developed prominent forelimb lameness after IL-1␤ injection on day 14, whereas one horse (subject 4) in the experimental group (injected with BoNT-A on day 0) developed clinically apparent lameness, and the remaining horse (subject 3) in the experimental group remained sound. Results of kinematic analysis of lameness (Fig. 2) indicate that in all horses, MINDIFF was near zero (indicating no lameness) before injection of IL-1␤. Both horses treated with placebo and one horse treated with BoNT-A had sharp rises in MIN-DIFF after IL-1␤ treatment, whereas one horse treated with BoNT-A remained sound (MINDIFF near zero).
FIGURE 1 Representative 5-m formalin-fixed sections of synovium taken from middle carpal joints injected with either interleukin-1 beta (IL-1␤) or saline on day 14 of study. A, One day after IL-1␤ injection. B, One day after saline injection. Histologic evidence of acute inflammation was observed in all joints injected with IL-1␤. Botulinum toxin type A injection on day 0 did not seem to attenuate histologic evidence of inflammation (left panel) observed on day 15 (1 day after IL-1␤ injection). Stain: hematoxylin and eosin.
DISCUSSION
The present study was undertaken to model early-stage osteoarthritis and to evaluate the effects of early intervention with BoNT-A. Osteoarthritis in horses is one of the most common and difficult problems encountered by veterinarians; like osteoarthritis in humans, it leads to deterioration of the articular cartilage and pathologic changes in the bone and soft tissues of the joint, and it eventually causes lameness. 32 Although a wide range of treatments and therapeutic strategies have been employed, our ability to prevent the onset of osteoarthritis is limited, and there is no cure for the disease. Here, we tested the hypothesis that BoNT-A might attenuate the lameness associated with acute synovitis in horses. This idea is partly supported by the positive response in one of the two horses that received BoNT-A in the present study. Reasons for the lack of response in the second horse are not clear and will require additional study.
Interleukin-1 has been implicated in the induction and augmentation of the pathologic processes involved in arthritis and articular cartilage destruction. 33 It was used in the present investigation to experimentally induce acute synovitis and pain in the midcarpal joints of horses. Indeed, acute supporative inflammation was observed within 24 hrs in joints injected with IL-1␤. This finding supports the idea that IL-1␤ can induce a cellular inflammatory response similar to that observed in the acute stages of osteoarthritis and during osteoarthritis "flare" episodes. 34, 35 Horses develop osteoarthritis with a frequency and degree of severity similar to that of human patients. 36 A considerable degree of homology between human and equine IL-1 has been demonstrated, 37 and equine IL-1 has many of the characteristics of IL-1 isolated from other species. Therefore, the present findings have direct implications for humans with early osteoarthritis and pain from synovitis.
None of the horses in this study became lame or developed signs of synovitis after intra-articular injection of BoNT-A or saline. Intra-articular injection of BoNT-A was well tolerated and was not associated with any detectable adverse clinical effects. Only one of two treatment subjects responded favorably, demonstrating no evidence of lameness after IL-1␤ injection; this observation is surprising, given the profound and severe lameness observed after IL-1␤ injection in the remaining three subjects. It should be noted that the present pilot study included only a small sample size (n ϭ 4) and that further controlled studies are required to support or refute any positive findings reported here.
Clinical Implications
There currently exist only a limited number of safe, effective pharmacologic interventions for the management of pain associated with inflammatory joint disease such as osteoarthritis. Simple analgesics, opioids, and nonsteroidal antiinflammatory drugs all have significant limitations with respect to efficacy, duration of effect, patient acceptability, safety, and tolerability. 38 -40 Only recently have a new class of agents, the hyaluronans, become available to clinicians for the treatment of painful osteoarthritis. 41 Here, we have explored the effects of a totally new class of agents-biological neurotoxins-in an acute inflammatory model of pain. In the present study, we present the first objective evidence of an analgesic response after intra-articular BoNT-A in an equine model of acute inflammatory synovitis of the midcarpal joint. Our findings in horses support the findings of an open-label observational study in humans with painful joints. In a previous study, Mahowald and collegues 2 have reported clinical benefit from intra-articular injections of BoNT-A for refractory painful arthritis. In the present study, we report preclinical data that provide further support for the idea that BoNT-A can provide an analgesic effect separate from its better-known effect at the neuromuscular junction. 16 Given the favorable safety profile for BoNT-A, [42] [43] [44] it is encouraging to consider the possibility that BoNT-A may emerge as a new treatment for patients with painful arthritis.
CONCLUSION
The results of this small pilot study support the hypothesis that intra-articular treatment with BoNT-A can attenuate lameness associated with acute synovitis in horses. Further evaluation with larger numbers of subjects is justified by the present findings.
